USP Gives Manufacturers More Time to Meet Residual Solvent Standards
This article was originally published in The Gold Sheet
The U.S. Pharmacopeia recently announced a one-year delay in requiring manufacturers to conform to residual solvent standards. Originally slated to take effect on July 1, 2007, the standards will now go into effect on July 1, 2008
You may also be interested in...
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.